The Respiratory Epithelial Barrier as an Immunopharmacological Rheostat: From Homeostatic Sentinel to Therapeutic Target in Chronic Lung Disease.

The respiratory epithelium is a dynamic immunopharmacological interface that transcends its traditional role as a passive barrier to become a central coordinator of pulmonary immunity. This review introduces and elaborates on the paradigm of the "Epithelial Immunopharmacological Rheostat," a conceptual framework that posits the epithelium as a dynamic, multidimensional signal processor that continuously calibrates the threshold of immune activation. Distinct from static models of barrier dysfunction or isolated alarmin biology, this rheostat operates through four hierarchically interacting axes: barrier integrity, alarmin/type 2, senescence/repair, and tolerogenic programming. We critically dissect how dysregulation of specific axes-alone or in combination-initiates and perpetuates the pathology of chronic respiratory diseases, including asthma, COPD, and idiopathic pulmonary fibrosis. A rigorous, pharmacology-centric analysis deconstructs the molecular circuitry of epithelial-immune crosstalk, evaluating the druggability of targets from tight junction complexes and pattern recognition receptors to the alarmin (TSLP, IL-33, IL-25) signaling cascades and their downstream JAK-STAT, NF-κB, and MAPK effectors. Beyond cataloguing mechanisms, this review provides a comparative and critical appraisal of emerging therapeutic strategies, including alarmin-targeted biologics, barrier-restorative agents (e.g., postbiotics, short-chain fatty acids), kinase inhibitors, senotherapeutics, and frontier cell-based therapies. A dedicated synthesis addresses pivotal pharmacokinetic hurdles, biomarker-driven stratification, and the imperative of precision endotyping. Finally, we forecast how advanced human organoid models are catalyzing the shift toward personalized interventions designed to reset the defective rheostat. This comprehensive synthesis maps the intricate landscape of epithelial immunopharmacology and identifies critical barriers that must be overcome to translate these insights into transformative clinical outcomes.